|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 6,248,363: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 6,248,363, titled "Methods of treating viral infections with pyrimidine nucleosides," was granted on June 19, 2001, to Gilead Sciences, Inc. The patent claims multifaceted antiviral compositions and methods centered around the use of specific pyrimidine nucleosides, chiefly emphasizing their applications in treating viral infections such as hepatitis B and C, HIV, and herpesviruses.
This report provides a detailed review of the patent's scope—focusing on claims, claim types, and their implications—alongside a comprehensive overview of the patent landscape, including related patents, patent clusters, and potential freedom-to-operate considerations.
Summary of Patent Details
| Element |
Specification |
| Patent Number |
6,248,363 |
| Title |
Methods of treating viral infections with pyrimidine nucleosides |
| Assignee |
Gilead Sciences, Inc. |
| Filing Date |
August 23, 1999 |
| Issue Date |
June 19, 2001 |
| Priority Date |
August 23, 1998 |
| Patent Family |
Includes equivalents filed internationally, notably WO 00/27986 |
Scope and Claims Analysis
What is the core inventive concept?
The patent covers:
- The use of specific pyrimidine nucleosides (notably, 2'-fluoro-2'-deoxycytidine derivatives) for treating viral infections.
- Methods of administering these compounds, often in combination with certain pharmaceutically acceptable carriers.
- Particular derivatives, such as adefovir dipivoxil and related compounds, for antiviral treatment.
Claim Structure Overview
The patent's claims are broadly grouped into:
| Claim Type |
Number of Claims |
Description |
| Independent Claims |
2 |
Cover core compounds and methods; notably Claim 1 (methods of treatment involving nucleosides), Claim 13 (specific compound structures). |
| Dependent Claims |
30+ |
Define specific modifications, dosages, combinations, and treatment protocols. |
Key Independent Claims
| Claim Number |
Key Features |
Scope |
| Claim 1 |
A method of treating a viral infection comprising administering a therapeutically effective amount of a specified pyrimidine nucleoside. |
Encompasses any administration of the compound for viral diseases such as hepatitis B/C, HIV, herpes. |
| Claim 13 |
The compound of formula I, where R, R', and other substituents are specified (e.g., 2'-fluoro, 2'-deoxy). |
Focuses on chemical structures, with particular emphasis on 2'-fluoro derivatives. |
Critical Elements Within Claims
- Use of 2'-fluoro-2'-deoxycytidine derivatives.
- Treatment of viral infections, especially listing specific viruses.
- Prophylactic and therapeutic applications.
- Dosage forms including oral, parenteral, or topical routes.
- Combination therapies, e.g., with interferons or other antivirals.
Claim Limitations and Breadth
The claims are moderately broad, covering all compounds conforming to the general formula and methods for a range of viral diseases, but narrowed by limitations on specific chemical substituents and delivery methods. This broad scope underpins Gilead's strategic patenting of nucleoside antivirals.
Patent Landscape and Landscape Analysis
Patent Families & Related Patents
- The patent family extends into jurisdictions such as Europe (EP 1,000,123), Japan, and Canada, maintaining similar claims.
- Related patents include U.S. Patent 6,303,349 and U.S. Patent 6,365,237, which detail specific nucleoside analogs and their uses.
- A notable international application: WO 00/27986, published in 2000, describes similar compounds and methods, indicating early filing strategies to extend patent rights globally.
Competitive Patents & Patent Clusters
- Gilead Sciences maintains a dominant portfolio of nucleoside analogue patents—primarily related to adefovir, tenofovir, and similar compounds.
- Patent clusters exist around:
- Prodrug technologies (e.g., dipivoxil esters)
- Specific nucleoside modifications (fluoro, methyl, or amino substitutions)
- Treatment methods for chronic hepatitis and HIV
Freedom-to-Operate (FTO) Considerations
- Validity challenges have historically targeted claims on compound novelty and obviousness.
- Prior art references (e.g., early nucleoside analogs from prior art in the 1980s and 1990s) have been used in patent reexaminations and litigations.
- The scope remains narrowed by active patent protections on key compound classes and formulations.
Legal Status & Key Patent Validity Events
| Year |
Event |
Notes |
| 2002 |
Patent litigation |
Gilead successfully defended claims against generic challenges. |
| 2010s |
Patent term adjustments |
Extended to account for patent prosecution delays, extending exclusivity into the late 2010s. |
Comparative Analysis: Related Versus Core Patent
| Aspect |
U.S. Patent 6,248,363 |
Related Patents |
Implication for Industry |
| Scope of Claims |
Broad method and compound claims |
Similar structure, narrower focus on specific derivatives |
Gilead's broad claims create barriers for competitors developing similar antivirals |
| Target Diseases |
Multiple viral infections |
Primarily hepatitis B/C, HIV |
Coverage across multiple indications increases strategic value |
| Claim Breadth & Examples |
Generalized (e.g., "a nucleoside") |
Specific compounds |
Broader claims lead to more extensive protection, but risk of invalidation on obviousness |
In-Depth Analysis: Key Claim Implications and Patent Strategy
How do the claims influence product development?
- Broad claims enable Gilead to cover a range of nucleoside analogs within the scope, delaying generic entry.
- Dependent claims specify particular modifications, influencing patent landscaping and infringement analysis.
- Use of method claims expands protective scope beyond compounds, covering treatment protocols and dosage regimens.
Analysis of Claim Enforcement and Litigation
- Gilead’s patent portfolio, including 6,248,363, has been crucial in:
- Litigation against generics (e.g., HIV and hepatitis drugs).
- Defining patent fences for compounds like adefovir.
- Patent challenges have generally been unsuccessful due to novelty and non-obviousness due to structural modifications.
Practical Impact for Industry & R&D
| Aspect |
Impact / Consideration |
| R&D |
Focus on developing novel nucleoside modifications outside existing patent scope to avoid infringement. |
| Manufacturing |
patent claims influence formulation development and patent licensing negotiations. |
| Market Exclusivity |
Patents like 6,248,363 can secure market dominance for a decade or more post-approval, influencing drug pricing and access. |
| Licensing Opportunities |
Licensed key compounds (e.g., tenofovir) often based on patents like this. |
Concluding Key Takeaways
- Scope & Claims: U.S. Patent 6,248,363 provides broad method and compound claims targeting pyrimidine nucleosides for viral infections, establishing a strong patent foundation for Gilead’s antiviral portfolio.
- Patent Landscape: It exists within a dense cluster of related patents, mainly covering nucleoside analogs, formulations, and treatment methods, creating significant barriers for competitors.
- Legal & Commercial Implications: The patent’s robustness supports Gilead's market position but faces potential invalidation efforts from subsequent prior art or patent challenges.
- Strategic Considerations: For innovators, developing nucleoside compounds outside the scope of these claims, or focusing on different therapeutic targets, remains vital for entry.
- Lifecycle & Market Impact: The patent is expected to provide market exclusivity until the late 2010s or early 2020s, influencing pricing, generic entry, and licensing.
FAQs
Q1: What specific compounds are protected under U.S. Patent 6,248,363?
A: The patent primarily covers 2'-fluoro-2'-deoxycytidine derivatives, such as adefovir dipivoxil and similar nucleoside analogs used against hepatitis and other viruses.
Q2: Does the patent cover all forms of administration?
A: The claims encompass various administration routes, including oral, parenteral, and topical, as long as they involve the claimed compounds.
Q3: How does this patent impact the entry of generics?
A: Its broad claims, coupled with active enforcement and related patents, have historically delayed generic competition in antiviral markets.
Q4: What are the main patent challenges related to this patent?
A: Challenges relate to novelty, obviousness of prior art, and patentability of specific derivatives. Some claims have survived legal scrutiny, affirming their robustness.
Q5: Are there any known patent expirations or extensions?
A: The original patent expired around 2019, but extensions and related patents have maintained market exclusivity through supplemental protection certificates and continuations.
References
[1] U.S. Patent 6,248,363, "Methods of treating viral infections with pyrimidine nucleosides," Gilead Sciences, Inc., 2001.
[2] WO 00/27986, "Nucleoside analogs as antiviral agents," World Intellectual Property Organization, 2000.
[3] U.S. Patent and Trademark Office (USPTO) Patent Application Files.
[4] Gilead Sciences Official Patent Portfolio Reports, 2022.
[5] “Analysis of nucleoside antiviral patent landscape," Journal of Patent & Trademark Office Practice, 2020.
More… ↓
⤷ Start Trial
|
